Dendreon Company Profile (NASDAQ:DNDN)

About Dendreon (NASDAQ:DNDN)

Dendreon logoDendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company's product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company's product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DNDN
  • CUSIP: 24823Q10
  • Web:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.32
  • P/E Growth: N/A
  • Dividend Yield: 1.0%
  • Net Margins: -30.18%
  • Return on Assets: -25.12%

Frequently Asked Questions for Dendreon (NASDAQ:DNDN)

What is Dendreon's stock symbol?

Dendreon trades on the NASDAQ under the ticker symbol "DNDN."

How were Dendreon's earnings last quarter?

Dendreon Co. (NASDAQ:DNDN) issued its quarterly earnings results on Monday, November, 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.04. The company had revenue of $73.10 million for the quarter, compared to analyst estimates of $78.72 million. The firm's quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business posted ($0.44) EPS. View Dendreon's Earnings History.

Who are some of Dendreon's key competitors?

How do I buy Dendreon stock?

Shares of Dendreon can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dendreon's stock price today?

One share of Dendreon stock can currently be purchased for approximately $0.13.

MarketBeat Community Rating for Dendreon (NASDAQ DNDN)
Community Ranking:  1.1 out of 5 (star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  356 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Dendreon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Dendreon (NASDAQ:DNDN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Dendreon (NASDAQ:DNDN)
No equities research coverage for this company has been tracked by


Earnings History for Dendreon (NASDAQ:DNDN)
Earnings by Quarter for Dendreon (NASDAQ:DNDN)
Earnings History by Quarter for Dendreon (NASDAQ DNDN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2014Q3($0.10)($0.14)$78.72 million$73.10 millionViewN/AView Earnings Details
8/20/2014($0.18)($0.18)ViewN/AView Earnings Details
8/11/2014($0.25)($0.10)$73.37 million$82.16 millionViewN/AView Earnings Details
5/8/2014Q114($0.28)($0.24)$69.19 million$68.70 millionViewListenView Earnings Details
3/3/2014Q413($0.37)($0.17)$73.59 million$74.80 millionViewListenView Earnings Details
11/12/2013Q313($0.42)($0.44)$76.60 million$68.00 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.42)($0.45)$75.61 million$73.30 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.47)($0.48)$80.15 million$67.60 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.56)($0.26)$82.88 million$85.49 millionViewN/AView Earnings Details
11/2/2012Q312($0.75)($0.33)$80.68 million$78.00 millionViewN/AView Earnings Details
5/2/2011($0.70)($0.77)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Dendreon (NASDAQ:DNDN)
Current Year EPS Consensus Estimate: $-0.730 EPS
Next Year EPS Consensus Estimate: $-0.400 EPS


Dividend History for Dendreon (NASDAQ:DNDN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Dendreon (NASDAQ:DNDN)
No insider trades for this company have been tracked by


Headline Trends for Dendreon (NASDAQ:DNDN)
Latest Headlines for Dendreon (NASDAQ:DNDN)
DateHeadline logoDendreon (DNDN) vs. Soligenix (SNGX) Financial Survey - August 18 at 8:10 PM logoValeant completes Dendreon sale to Sanpower for ~$820M; Cantor bullish, boosts price target to $23; shares ahead 4% premarket - June 29 at 7:49 AM logoJim Cramer on L'Oreal's Deal for Valeant's Skin Care Lines - - January 10 at 12:48 PM logoValeant sells Dendreon for $819.9M - January 9 at 11:29 PM logoConsultant: 'There may be no profitable biotechs in Seattle,' and that's OK - September 7 at 4:47 PM logoFDA shuts down CTI Bio's pacritinib clinical trials; shares down 46% premarket - Seeking Alpha - February 10 at 4:40 PM logoAre MannKind's Lenders Calling The Shots? - Seeking Alpha - January 19 at 4:03 PM logoMy Favorite Under $5 Biotech Could Soar 150% or More - May 6 at 8:08 AM logoThe First Rule of Short Selling Is: Don’t Talk About Short Selling - March 12 at 11:39 PM logoDendreon’s Enhanced $445 Million Sale to Valeant Approved - February 20 at 2:06 PM logoValeant to buy bankrupt vaccine maker Dendreon - February 10 at 5:51 PM logoDendreon’s Price Jumps 35% Before Bankruptcy Auction Even Starts - February 5 at 1:19 PM logoDendreon's Asset Rummage Sale Completes the Circle of Life - January 30 at 6:01 AM logoValeant to buy Dendreon's prostate cancer vaccine Provenge - January 29 at 11:01 PM logoValeant to buy worldwide rights to Dendreon's Provenge - January 29 at 9:29 PM logoDendreon heads to auction without initial bidder - December 29 at 4:40 PM logoDendreon's Dead Enders Still Blaming Everyone But Themselves - November 10 at 2:11 PM logoDendreon files for Ch. 11 bankruptcy protection - November 10 at 1:31 PM logoUPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints - November 10 at 12:42 PM logoThe Shame and Lessons of a Dendreon Bankruptcy - November 10 at 8:15 AM logoDendreon files for Chapter 11 bankruptcy - November 10 at 2:22 AM logoIs an Impending Implosion of Dendreon Avoidable? - August 12 at 12:54 PM logoApple And Others Should Issue Debt Now - January 27 at 12:18 AM



Dendreon (DNDN) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff